-
Company Insights
Innovation and Patenting activity of Frontline Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Frontline Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Thematic Analysis
NewGeopolitics – Executive Briefing (First Edition)
Reasons to buy the ‘Geopolitics - Executive Briefing’ report: The report provides in-depth insights into the global geopolitical stance. Explore a global geopolitical risk map highlighting level of severity and a summary on the 2024 elections. Identify the frontline sectors exposed to global geopolitics. The report sheds light on the politics of the major countries that shape geopolitics. How is the ‘Geopolitics - Executive Briefing’ report different from other reports in the market? This executive briefing report explores the drivers...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Follicular Lymphoma Drug Details: Venetoclax (ABT-199, GDC-0199/RG7601, Venclexta, Venclyxto)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Myelodysplastic Syndrome Drug Details: Venetoclax (ABT-199, GDC-0199/RG7601, Venclexta, Venclyxto)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Small-Cell Lung Cancer Drug Details: Venetoclax (ABT-199, GDC-0199/RG7601,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Chronic Myelomonocytic Leukemia (CMML) Drug Details: Venetoclax...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Rhabdomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Rhabdomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Rhabdomyosarcoma Drug Details: Venetoclax (ABT-199, GDC-0199/RG7601, Venclexta, Venclyxto) acts as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Neuroblastoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Neuroblastoma Drug Details: Venetoclax (ABT-199, GDC-0199/RG7601, Venclexta, Venclyxto) acts as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Solid Tumor Drug Details: Venetoclax (ABT-199, GDC-0199/RG7601, Venclexta, Venclyxto)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Amyloidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Amyloidosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Amyloidosis Drug Details: Venetoclax (ABT-199, GDC-0199/RG7601, Venclexta, Venclyxto) acts as...